Financials in USD. Standardized financial statements.
A compact view of how Fate Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $6.65M | $13.63M | $63.53M | $96.30M | $55.85M | $31.43M | $10.68M | $4.74M | $4.11M | $4.40M |
| Revenue Growth? | -51.2% | -78.5% | -34.0% | +72.4% | +77.7% | +194.3% | +125.3% | +15.4% | -6.7% | 0.0% |
| Cost of Revenue? | $12.90M | $0 | $157.19M | $13.76M | $5.85M | $125.62M | $0 | $56.02M | $34.36M | $26.45M |
| Gross Profit? | -$6.25M | $13.63M | -$93.65M | $82.54M | $50.00M | -$94.19M | $10.68M | -$51.28M | -$30.25M | -$22.05M |
| Gross Margin? | -94.1% | +100.0% | -147.4% | +85.7% | +89.5% | -299.6% | +100.0% | -1081.9% | -736.8% | -500.9% |
| Operating Expenses? | $141.45M | $223.91M | $96.86M | $390.93M | $266.99M | $33.90M | $111.41M | $71.83M | $46.23M | $36.37M |
| Operating Income? | -$147.70M | -$210.28M | -$190.51M | -$308.39M | -$216.99M | -$128.09M | -$100.73M | -$67.09M | -$42.13M | -$31.96M |
| EBITDA? | -$127.02M | -$176.58M | -$172.23M | -$294.63M | -$211.14M | -$125.00M | -$94.20M | -$63.70M | -$40.71M | -$30.94M |
| Income Before Tax | -$136.31M | -$186.26M | -$160.93M | -$281.72M | -$212.15M | -$173.39M | -$98.15M | -$66.60M | -$42.95M | -$33.46M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $297,000 | $0 |
| Net Income? | -$136.31M | -$186.26M | -$160.93M | -$281.72M | -$212.15M | -$173.39M | -$98.15M | -$66.60M | -$42.95M | -$33.46M |
| EPS? | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 | $-1.43 | $-1.19 | $-1.02 | $-1.05 |
| Diluted EPS? | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 | $-1.43 | $-1.19 | $-1.02 | $-1.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality